1.	Phase I/II Randomized Study of Pre-Operative Androgen-Ablation Therapy With Versus Without Hedgehog Antagonist GDC-0449 Followed by Radical Prostatectomy in Patients With Locally Advanced Adenocarcinoma of the Prostate Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: MDA-2009-0473, 2009-0473, 8384, NCT01163084
2.	Phase I/II Partially Randomized Study of Hedgehog Antagonist GDC-0449 in Combination With Gamma-Secretase Inhibitor RO4929097 in Patients With Advanced or Metastatic Sarcoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-10049, 10-049, 8406, NCT01154452
3.	A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SHH4429g, NCT00636610
4.	A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SHH4489g, NCT00739661
5.	A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SHH4476g, GO01541, NCT00833417
6.	Phase II Randomized Study of Cisplatin and Etoposide Phosphate With or Without Hedgehog Antagonist GDC-0449 or Cixutumumab in Patients With Extensive Stage Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E1508, E1508, NCT00887159
7.	The Purpose of This Study is to Determine The Efficacy and Safety of a Systemic Hedgehog Pathway Antagonist (GDC-0449) in Patients With Basal Cell Nevus Syndrome (BCNS) Phase: Phase II Type: Treatment Status: Closed Age: 35 to 75 Sponsor: Other Protocol IDs: 2009-026, SHH-4685s, NCT00957229
8.	GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: ABTC-0904 CDR0000654829, U01CA137443, ABTC-0904, 0904, NCT00980343
9.	Phase II Randomized Study of FOLFOX Chemotherapy With Versus Without Vismodegib in Patients With Advanced Gastric or Gastroesophageal Junction Carcinoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NYCC-09-0356, NYU 09-0356, 8376, NCT00982592
10.	Phase II Randomized Study of Gemcitabine Hydrochloride With Versus Without Hedgehog Antagonist GDC-0449 in Patients With Recurrent or Metastatic Pancreatic Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 21 and over Sponsor: NCI Protocol IDs: UCCRC-8418, 8418, NCT01064622
11.	Phase II Study of Hedgehog Antagonist GDC-0449 in Patients With Advanced Chondrosarcomas Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: IB-CHONDROG, NCI-8408-CHONDROG, 8408, NCT01267955
12.	GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 3 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000631677, U01CA081457, PBTC-025, NCT00822458
13.	GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CDR0000585468, JHOC-J06131, GENETECH-SHH3925g, J06131, NCT00607724
14.	Phase I Study of Hedgehog Antagonist Vismodegib and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Patients With Metastatic Pancreatic Cancer or Unresectable Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MAYO-MC0811, MC0811, 8231, NCT00878163
15.	A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SHH4610g, NCT00968981
16.	Evaluation of Food Effect on Pharmacokinetics of GDC-0449 Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 09-149-B, NCI 8395, NCT01174264
17.	A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SHH4593g, NCT01209143